MBrace Therapeutics’ Post

🚀 Diving into the Biotech World: In this must-listen episode of "The Readout LOUD," explore the turbulent waters of biotech startups fighting for survival amid funding droughts, witness Gilead Sciences' tough journey towards conquering the oncology market, and unravel the strategic implications behind Inhibrx's recent acquisition. Insightful, informative, and at the industry's cutting edge – tune in for a deep dive into the heart of biotech's most pressing issues. #Biotech #VentureCapital #Oncology #GileadSciences #Inhibrx #TheReadoutLOUD #Innovation #PodcastDigest #HealthcareTrends 🧬💡🎙️

Exclusive: FogPharma just closed a $145 million Series E round from around 18 investors, reaching a late stage of financing that few other biotechs have hit in recent years. I spoke to CEO Mathai Mammen, M.D., Ph.D. about his plans for partnerships and pruning some drugs from the biotech's pipeline. “Life is short. Let’s try, at least, to focus on extraordinary drugs. Try our very best not to do anything incremental, but some things that are kind of earth-moving,” he told STAT. #biotech #biopharma #lifesciences #startups #startupfunding #venturecapital #VC #ceoinsights #drugdevelopment #oncology #cancertreatment #clinicaltrials

💵 Biotech & pharma fundraising slowed last week. Even still, there were multiple important deals. These are the 8 financings not to miss… 👇 ➡️ PUBLIC ⬅️ 👁️ Ocular Therapeutix, Inc. secured $325M in a private placement led by Venrock and Perceptive Advisors. The funds will accelerate the Phase 3 trials of AXPAXLI for wet AMD and support other clinical programs. 🧬 Prime Medicine, Inc. closed an upsized public offering, raising ~$161M. The company specializes in developing potentially curative one-time gene therapies using its Prime Editing platform. 🔬 Chromocell Corporation closed its IPO with $6.6M in proceeds. The clinical-stage biotech creates novel non-opioid treatments for pain, with a focus on NaV1.7 targeting for chronic neuropathic pain and eye pain. ➡️ PRIVATE ⬅️ 🤖 Medical Microinstruments, Inc. (MMI) secured $110M in a Series C led by Fidelity Investments. The investment supports the commercialization of the Symani® Surgical System for microsurgeries and expands MMI's global operations. 🔬 Frontier Medicines closed an oversubscribed $80M Series C co-led by Deerfield Management and Droia Ventures. Funds will support clinical trials of their lead candidate, FMC-376, a potential best-in-class therapy for KRASG12C cancers.   🫀 Reprieve Cardiovascular raised $42M in a Series A co-led by Lightstone Ventures and Sante Health Ventures II LP. The company specializes in fluid management for acute decompensated heart failure and will advance clinical trials including the FASTR trial.   🧬 Bioptimus launched with a $35M seed round led by Sofinnova Partners, aiming to revolutionize biology with a universal AI foundation model. The team includes alumni from Google DeepMind and Owkin. Funds will support advancements in biomedicine and scientific research. 🛡️ Cagent Vascular secured over $30M in a Series C led by U.S. Venture Partners. Funds will boost U.S. market adoption and expand their Serration Angioplasty Technology portfolio for treating Peripheral Artery Disease (PAD).

The founders of UPyTher (member of SBMC) had an exceptional summer: 🔬 Secured €2.8 Million Grant: In collaboration with SupraPolix BV (another SBMC-member), UPyTher is pushing boundaries to develop a novel therapy for peritoneal cancer, supported by the European Commission (#OPZuid) and Provincie Noord-Brabant. 💡 Seed Financing Success: UPyTher has successfully attracted seed funding to advance its lead product, UPT-211, bringing the company closer to clinical trials. 🏆 Prestigious Award: UPyTher is proud to have received the Anton and Gerard Award, a testament to the team’s hard work and dedication. Co-founder Geert van Almen reflects in this interview on UPyTher’s journey from academia to a startup, emphasizing the importance of agility, partnerships with key opinion leaders (at Catharina Ziekenhuis a.o.) and the invaluable support from investors like BOM (Brabantse Ontwikkelings Maatschappij) Essential Investments BV and #TTT Medtech. 🚀 Next up? Scaling production methods and preparing for pivotal preclinical studies. UPyTher is just getting started! Read the full article to learn more about UPyTher's journey #Innovation #Healthcare #CancerResearch #Startup #Funding #Biotech #UPyTher #RegmedXB Innovation Origins NL #RegmedXB

Startups, what do you see as the greatest challenge in oncology R&D?  This Johnson & Johnson Innovation – JLABS program is designed to equip you with crucial insights, including:   - Establishing proof-of-concept - Navigating clinical trial complexities - Standing out in this competitive field   Access to expertise and resources are key in overcoming challenges in oncology R&D. Join J&J scientists, industry leaders and entrepreneurs as they share how they’ve tackled their most daunting challenges.   Innovators can register here: https://jji.jnj/3v75WzL   #Biotech #startups #oncology #jnjinnovation #innovation #clinicaltrials #research #development #researchanddevelopment #drugdevelopment

🚀 Exciting news! DeepCure, a pioneer in AI-driven small molecule therapeutics, has secured $24.6M in Series A-1 funding led by IAG Capital Partners. 🌟 This investment will propel advancements in immunology, inflammation, and automation capabilities for drug discovery. 💼 With participation from existing investors, DeepCure has now raised over $72M. Read more: [Link to full article] https://lnkd.in/dFTd2sGW #DeepCure #AI #DrugDiscovery 🧪🔬

Maryland's Tech Scene is on 🔥 with TEDCO's $2.7M Investments in Q1! From agtech to cancer therapeutics, these investments are driving growth and pushing boundaries. 🌱 Here's a glimpse into TEDCO's investments in 2024 so far: - Aloe Therapeutics - $100K investment - IPGen - $150K investment - LAZARRUS - $50K investment - Innate Technologies - $500K investment - Sonogen Medical Inc. - $200K investment - Minnowtech - $200K investment - Linshom Medical, Inc. - $400K investment - Pathotrak - $300K investment - Impruvon Health - $300K investment - Tomorrow’s Bio Today - $25K investment - PediaMetrix - $200K investment - Rendr - $300K investment Let's continue to fuel the fire of innovation together! 🔥 Read More: https://lnkd.in/e2XXUsAf #TEDCO #Innovation #MarylandTech #Biotech #Investment #StartupEcosystem

With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies https://lnkd.in/gtUqWBUp Seattle startup Outpace Bio, a Lyell Immunopharma spinout using AI to design proteins for solid tumor cell therapies, has raised a $144 million Series B to gather clinical data from its first two programs. It’s the 60th megaround of the year for private biotech companies, but Outpace didn’t originally have plans for a nine-figure raise. Investors kept piling in, though, CEO Marc Lajoie said in an interview. RA Capital Management led the round, which was announced Thursday. Bristol Myers Squibb, Artis Ventures and other existing backers from Outpace’s $30 million Series A from 2021 also joined the new funding. Qatar Investment Authority, Surveyor Capital, Sheatree Capital, Black Opal Ventures, Alexandria Venture Investments and others invested in Outpace for the first time. The company is slated to enter the clinic next year with a mesothelin autologous CAR-T known as OPB-101, Lajoie said. In the past, Outpace looked at… Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Switzerland is one of the global leaders in life science. But who are the innovators that shape the future of #biotech? Check out what the startup community thinks. An update of the TOP 100 Public Voting: https://lnkd.in/dMwsPy6f TOP 3 in Biotech as of May 13: 1. Recolony AG: The startup focus is fighting cancer with a two-pronged approach. The first product is a unique, orally-delivered LBP targeting various solid tumors. This bacterial therapy works by stimulating specific immune cells through a well-defined mechanism, which Recolony has identified. https://lnkd.in/dv8bvkpB 2. HAYA Therapeutics: HAYA is dedicated to treating heart failure through the discovery and development of innovative first-in-class RNA-based therapeutics, with a specific focus on long noncoding RNAs. https://lnkd.in/dMbtRSP3 3. Navignostics AG: The startup characterizes tumors using spatial single-cell proteomics. It identifies a cancer treatment that will optimally fight each patient's tumor. https://lnkd.in/eH84t9q3 The race is still wide open, so keep spreading the word! Startups can share the link to the startup.ch voting page with friends, family, and followers and encourage everyone in the network to vote for them. Remember, every vote counts! How you can vote for your favorite TOP 100 Swiss startup: Voting is as easy as 1-2-3: 1. Visit https://lnkd.in/eNkbHTb9 for a list of all eligible startups. 2. Choose your winning startup and click the golden “Vote now” button on the startup’s profile. 3. Log in with your LinkedIn profile. Each user has one vote. Happy voting! All votes have to be in by July 21, 2024, at midnight. #TOP100SSU #SwissStartups #Switzerland

Congratulations to Alex, Lindsay, Michelle, and the rest of the Talus Bio team on the latest financing! This will be transformative for the team as they work to develop new drugs to target transcription factors. 👩🔬 What does the company do? Talus uses their platform to test for the effect of novel TF-targeted drugs in a live cell opening up the possibility of drugging many previously 'undruggable' targets. 💊 What do they have so far? The company is working on four targets including #brachyury for treating a rare cancer called #chordoma. 💸 Who is investing? The round is led by a stellar team at Two Bear Capital (J. Seth Strattan PhD and Avery Sonnenberg), with participation from Washington Research Foundation, BoxOne Ventures, and NFX 🌎 Why does this matter? Talus has an impressive technology that hopefully can create new treatment options for some serious conditions. The team worked doggedly to build the company off of grants in a harsh market cycle and this investment validates how far they've come. I'm excited to have this team in Seattle helping build the next generation of great biotech companies here! #biotech #financing #company #seattle